HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech Risk Assessment Comments Sought By EU Commission

This article was originally published in The Rose Sheet

Executive Summary

The European Commission is seeking comments on current risk assessment methods for nanotechnology as well as suggested improvements, the EC Health & Consumer Protection Directorate General announced Oct. 20

You may also be interested in...



Nanoparticle Research Priorities Outlined In UK Report

Further information is needed regarding dermal uptake, penetration and toxicity of nanoparticles in consumer products, according to a recent report by the UK Department for Environment, Food and Rural Affairs

Nanoparticle Research Priorities Outlined In UK Report

Further information is needed regarding dermal uptake, penetration and toxicity of nanoparticles in consumer products, according to a recent report by the UK Department for Environment, Food and Rural Affairs

Nanotechnology Potential Developments May Include Nomenclature

The development of a nomenclature standard for nanomaterials is a topic that will be addressed by The National Toxicology Program's Board of Scientific Counselors' Nanotechnology Working Group in the future

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel